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Abstract
Numerous health beneﬁts are attributed to the n-3 long-chain PUFA (n-3 LCPUFA); EPA and DHA. A systematic literature review was
conducted to investigate factors, other than diet, that are associated with the n-3 LCPUFA levels. The inclusion criteria were papers written in
English, carried out in adult non-pregnant humans, n-3 LCPUFA measured in blood or tissue, data from cross-sectional studies, or baseline
data from intervention studies. The search revealed 5076 unique articles of which seventy were included in the qualitative synthesis. Three
main groups of factors potentially associated with n-3 LCPUFA levels were identiﬁed: (1) unmodiﬁable factors (sex, genetics, age),
(2) modiﬁable factors (body size, physical activity, alcohol, smoking) and (3) bioavailability factors (chemically bound form of supplements,
krill oil v. ﬁsh oil, and conversion of plant-derived α-linolenic acid (ALA) to n-3 LCPUFA). Results showed that factors positively associated
with n-3 LCPUFA levels were age, female sex (women younger than 50 years), wine consumption and the TAG form. Factors negatively
associated with n-3 LCPUFA levels were genetics, BMI (if erythrocyte EPA and DHA levels are <5·6 %) and smoking. The evidence for girth,
physical activity and krill oil v. ﬁsh oil associated with n-3 LCPUFA levels is inconclusive. There is also evidence that higher ALA consumption
leads to increased levels of EPA but not DHA. In conclusion, sex, age, BMI, alcohol consumption, smoking and the form of n-3 LCPUFA are all
factors that need to be taken into account in n-3 LCPUFA research.
Key words: Fatty acid status: Effects: Determinants: Healthy adults: Review studies: Measurement: Implications

n-3 Long-chain PUFA (n-3 LCPUFA) are fatty acids with twenty
or more carbons, and they are the elongation and desaturation
products of the essential fatty acid α-linolenic acid (ALA,
18 : 3n-3). Whilst there are emerging health beneﬁts of docosapentaenoic acid (DPA, 22 : 5n-3)(1), the vast majority of
health beneﬁts have been attributed to the n-3 LCPUFA EPA
(20 : 5n-3) and DHA (22 : 6n-3)(2).
n-3 LCPUFA have been shown to be important for neurological development in very early pregnancy(3), during later
pregnancy and lactation(4) and cardiovascular health(5,6) and
there is also emerging evidence for mental health(7). Several
mechanisms have been suggested(8), such as their structural
role in the cell membrane inﬂuencing signal transduction,
stimulating neuronal growth, inﬂuencing neurotransmitter
release and facilitating glucose uptake from the endothelial cells
into the brain. n-3 LCPUFA are also important precursors of the

eicosanoids, resulting in reduced blood clotting and increased
blood ﬂow(8). DHA is a precursor of docosanoids such as
resolvins and maresins, resulting in anti-inﬂammatory effects(9)
and neuroprotectins which protect neurons(8).
The aforementioned potential health beneﬁts have been
observed from a wide variety of evidence including epidemiological, observational studies and randomised controlled
trials. However, many studies have failed to measure the n-3
LCPUFA in blood or tissue, and this may severely limit the
interpretations of the results as these n-3 LCPUFA might be
inﬂuenced by many factors besides intake.
It is well established that diet and supplementation with n-3
LCPUFA have the largest impact on n-3 LCPUFA levels(10);
however, research has indicated that factors other than diet also
play a role(11). As researchers may not be aware of the many
non-dietary factors associated with the n-3 LCPUFA levels

Abbreviations: ALA, α-linolenic acid; DPA, docosapentaenoic acid; FADS, fatty acid desaturase; n-3 LCPUFA, n-3 long-chain PUFA; PL, phospholipids; SDA,
stearidonic acid.
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Downloaded from https://www.cambridge.org/core. University of Wollongong, on 14 Mar 2019 at 04:34:20, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114519000138

British Journal of Nutrition, page 1 of 16
doi:10.1017/S0007114519000138
© The Authors 2019. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the
original work is properly cited.

R. H. M. de Groot et al.

per se, and the way these can inﬂuence the study outcomes, the
aims of the present paper are to (1) report the results of a
systematic literature review of the well-described non-dietary
factors that are associated with the n-3 LCPUFA levels,
(2) identify important non-dietary factors that should be considered in future studies and (3) discuss whether measuring n-3
LCPUFA levels is necessary in research that assesses the health
beneﬁts of n-3 LCPUFA.

Methods
Search strategy
A Preferred Reporting Items for Systematic Reviews and MetaAnalysis (PRISMA) systematic literature search was conducted
using four different electronic databases (ProQuest, Medline,
Web of Science and Cochrane). The search was conducted in
June 2017 and covered all years up to June 2017. Appropriate
truncation and relevant indexing terms were used. Search terms
were related to (1) n-3 LCPUFA (e.g. n-3 fatty acids, EPA, DHA)
and (2) factors or determinants associated with/inﬂuencing n-3
LCPUFA levels (e.g. sex, age, genetics, body size, physical
activity, alcohol and smoking). An outline of the search strategy
is available in online Supplementary Table S1.

Comparison of n-3 long-chain PUFA levels across studies
For the present review ‘n-3 LCPUFA levels’ are used as an
umbrella term to describe the n-3 fatty acids with twenty or
more carbon atoms in any blood or tissue fractions measured.
We do not focus on DPA as it appears to have a poor association with diet in epidemiological studies (see Fig. 1(c) in
Sullivan et al.(12)). Please note that various comparable terminologies exist in the literature, including the Holman index;
the Lands highly unsaturated fatty acids(13); long-chain n-3
PUFA(14) and the Harris, von Schacky (HS)-n-3 index(15).
For comparison between different studies, we used the
available n-3 LCPUFA data and re-calculated them into erythrocyte EPA and DHA levels using the equations developed by
Stark et al.(16) where applicable.

with/inﬂuencing the n-3 LCPUFA levels. In that case, only
additional publications published after the release date of the
review publications on this respective factor were included.
Publications that did not meet these criteria based on abstract
review were excluded, and those that did were read in detail to
conﬁrm their inclusion. Further studies were then obtained
through hand searching the reference lists of these articles and
applying the above eligibility criteria. Quality checks were
performed and consensus on scores agreed on by all authors,
using either the National Heart Lung and Blood Institute
‘Quality Assessment Tool for Observational Cohort and CrossSectional Studies’ (at https://www.nhlbi.nih.gov/health-topics/
study-quality-assessment-tools)(17) or the Effective Public
Health Practice Project ‘Quality Assessment Tool For Quantitative Studies’ (at https://merst.ca/wp-content/uploads/2018/02/
quality-assessment-tool_2010.pdf)(18), depending on the type
of study.

Review of the literature
Eligible articles were categorised into groups, according to the
factors that they covered. The groups were unmodiﬁable
factors – ‘sex’, ‘genetics’ and ‘age’; modiﬁable factors – ‘body
size’, ‘physical activity’, ‘alcohol’ and ‘smoking’; and bioavailability factors – ‘chemically bound form of supplement’, ‘krill oil
v. ﬁsh oil’ and ‘conversion of plant-derived ALA to n-3 LCPUFA’.
Some articles covered more than one factor and were therefore
included in each group that they represented.
Four review articles were identiﬁed, wherein one evaluated the
association of sex with n-3 LCPUFA levels(19) and three reviewed
the bioavailability factors(20–22). We therefore did not execute a
full systematic review of the factors sex and bioavailability.

Results
The search returned 10 275 articles and after removal of duplicates 5076 articles remained. The ﬂow diagram (Fig. 1) outlines
the number of articles included after the screening and
eligibility criteria were applied.

Inclusion and exclusion criteria

Sex

The search results were screened based on the titles and
abstracts. Titles and abstracts which suggested the study identiﬁed one or more factors that are associated with the n-3
LCPUFA levels were selected and screened for eligibility.
Research studies met the inclusion criteria if (1) they were
written in the English language, (2) they were conducted in
humans, (3) the participants were at least 18 years of age,
(4) the participants were not pregnant, (5) the n-3 LCPUFA
levels were reported (EPA or DHA or both) and (6) they were
cross-sectional studies or were intervention studies that included baseline data; the results from the effects of n-3 LCPUFA
intervention studies were excluded (except for the factor
‘bioavailability’, because intervention studies are the only way
to determine this). In addition, (7) relevant previous review
publications were included if they focused on factors associated

A previous systematic literature review(19) demonstrated differences in plasma DHA (expressed as weight/weight percentage of total plasma fatty acids) between sexes; namely, women
had 0·12 % of total plasma fatty acids and 0·20 % of plasma
phospholipids (PL) higher than men (P = 0·002 and P < 0·00001,
respectively)(19). In participants aged 13–50 years, the DHA
values were signiﬁcantly higher in women (0·16 % of total
plasma fatty acids) compared with men; whereas the DHA
values did not differ when aged over 50 years(19). In high ﬁsh
intake groups, sex differences in DHA did not exist; however, in
low ﬁsh intake groups, the DHA was signiﬁcantly higher in
women (0·24 % of total plasma fatty acids)(19).
Since the publication of the systematic literature review(19),
one large study(23) showed that women from teens to aged 40
years had lower erythrocyte EPA and DPA compared with men,
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Identification
Screening

Records identified through
database searching
ProQuest = 2847
Medline = 3019
Web of Science = 2813
Cochrane = 1549

3

Additional records identified
through other sources (reference
lists and colleagues)
n 47

Titles and abstracts remaining after duplicates removed
n 5076
Records excluded (unlikely to meet
criteria based on title/abstract)
n 4898

Eligibility

Titles and abstracts that appeared potentially relevant
n 178

Full text articles not available
n 11

Full-text articles assessed for eligibility
n 167
Full-text articles excluded (not relevant, < 18
years of age, pregnant or breastfeeding
subjects, n-3 LCPUFA not measured, already
included in sex or bioavailability reviews)
n 97

Included

Studies included in
qualitative synthesis
n 70

Sex
n2
(includes one
review paper)

Genetics
n 16

Age
n 27

Body size
n 14

Physical activity
n8

Alcohol
n 12

Smoking
n 12

Bioavailability
n6
(includes three
review
papers)

Total from all above factors = 97
Note: Some articles were included in more than one factor

Fig. 1. Flow diagram of systematic literature review search. The flow diagram outlines the identification, screening, eligibility and inclusion process of the systematic
literature search. n-3 LCPUFA, n-3 long-chain PUFA.

but women from teens to age 30 years had higher erythrocyte
DHA levels compared with men.

Heritability
One study(10) identiﬁed that heritability (meaning the fraction of
phenotype variability that can be attributed to genetic variation)
explains 24 % of the variance of the n-3 LCPUFA levels, see
online Supplementary Table S2.

Genetics
Our systematic literature search revealed sixteen papers on the
association of the factor ‘genetics’ and n-3 LCPUFA levels, as
described subsequently.

Fatty acid desaturase. Nine studies were found, which looked
at the relationship between fatty acid desaturase (FADS)
genotypes and n-3 LCPUFA levels(24–32). A minor allele carrier

of a FADS SNP was negatively associated with plasma EPA in
six studies(24–26,29,31,32) and a negative association with DHA in
three of those studies(24,25,32). Three studies(27,28,30) found no
association between FADS minor allele carriers and plasma EPA
or DHA. In essence, minor allele carriers for FADS1 and FADS2
resulted in decreased plasma levels of γ-linolenic acid (GLA,
18 : 3n-6), arachidonic acid (AA, 20 : 4n-6) and 20 : 5n-3 (EPA)
(Table 1). The comparison of the major allele to the minor allele
(homozygous or heterozygous plus homozygous) for FADS1
and FADS2 and their effects on plasma fatty acid levels are
shown in Table 1.

Elongation of very-long-chain fatty acid 2. Three studies
were identiﬁed that looked at the relationship between elongation of very-long-chain fatty acid (ELOVL)2 and EPA, DPA
and DHA plasma levels(26,31,33). Two studies(31,33) observed
lower plasma DHA levels in minor allele carriers, whereas one
of them(31) saw higher EPA levels in minor allele carriers.
Another study(26) found no association of ELOVL2 rs953413 and
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InCHIANTI, a study involving people in Chianti in Italy; GOLDN, Genetics of Lipid Lowering Drugs and Diet Network Study in the USA; NR, not reported.
* NS, for the calculation of the average, NS was taken as being 0.
† The data in Table 1 are the fatty acid data taken from the publications that reported fatty acid data and then expressed as percentage increase or percentage decrease in the fatty acid compared with the major allele (no mutation). This is
a rough estimate of the magnitude of effect and therefore needs to be interpreted with caution.
‡ Limited data available as only one study reported this result.

NS
↓ 45
↑ 19‡
↑5
↓ 31
↑3
↑ 90‡
↓ 33
↓5
↓8
NS
↓ 20
NR
↑ 10
↓ 18
↑ 10
NR
↓ 13
↓9
↓ 10
NS
↓ 53
↑ 19
NR
↓ 39
NS
↑ 90
↓ 34
NR
↓ 15
NS
↓ 19
NR
↑ 11
↓ 18
NS
NR
↓ 16
↓ 10
↓ 10
↑7
NR
↓ 25
NR
↓ 27
↑ 10
NR
↓ 22
NR
NS
NS
↓ 61
NR
NS
↓ 37
NS
NR
↓ 50
NS
NS
18 : 2n-6
18 : 3n-6
20 : 2n-6
20 : 3n-6
20 : 4n-6
18 : 3n-3
20 : 3n-3
20 : 5n-3
22 : 5n-3
22 : 6n-3

↑3
↓ 19
NR
↑ 11
↓ 18
↑8
NR
↓ 17
↓9
↓ 11

↑ 13
NR
NR
NR
↓ 12
↑ 14
NR
↓ 14
↓7
NS

↑5
↓ 33
↓ 25‡
↑7
↓ 22
↑6
NR
↓ 24
↓7
↓4

NS
↓ 62
NR
NS
↓ 37
NS
NR
↓ 52
NS
NS

Al-Hilal(24)
Baylin(32)
Al-Hilal(24)
Tanaka (InCHIANTI)(31)
Gillingham(26)
Fatty acid

Al-Hilal(24)

Tanaka (GOLDN)(31)

FADS1 (average)

Gillingham(26)

rs3834458 (FADS2)
rs174583 (FADS2)
rs174537 (C10orf10, FADS1)
rs174561 (FADS1)

Table 1. Comparison of major allele with minor allele (homozygous or heterozygous plus homozygous) for fatty acid desaturase (FADS)1 and FADS2 on fatty acid levels
(Percentage increase or percentage decrease)*†

FADS2 (average)

R. H. M. de Groot et al.

plasma fatty acids (Table 2). The comparison of the major allele
to the minor allele (homozygous or heterozygous plus homozygous) for ELOVL2 and their effects on plasma n-3 LCPUFA are
shown in Table 2.

ApoE4. Only ﬁve studies were available on ApoE4, as shown in
Supplementary Table S2, and the results did not suggest a
strong relationship between ApoE4 and EPA or DHA plasma
levels(34–38). One study(34) found ApoE4 carriers had higher
plasma TAG EPA and DHA than non-carriers at baseline, but
baseline EPA and DHA levels were not shown to be different in
any of the participant groups in the additional four papers
reviewed(35–38) (online Supplementary Table S2).
Age
Twenty-six articles, which looked at ‘age’ as a factor associated
with n-3 LCPUFA levels, were included(10,23,39–62). Most publications reported plasma EPA and DHA and only four studies
reported erythrocyte levels of EPA and DHA(23,39,53,57). Twentyfour found a positive association, one found no association(57),
and another(54) an inverse association between age 40–60 and
age 61–82 years and n-3 LCPUFA (speciﬁcally DHA levels in
elderly women) (Figs. 2 and 3). See online Supplementary Table
S3 for detailed information on the range of age groups and the
relevant outcomes for each of the twenty-six studies reviewed.
Plasma EPA and DHA levels are positively associated with
age in the majority of studies. Erythrocyte EPA and DHA levels
only tended to be positively associated with age in adults(39,53),
with only statistical signiﬁcance shown in men(53). One study
did not show associations with increased age(57). One large
study(23) showed that the net effect on erythrocyte EPA and
DHA was an overall 7 % increase per decade up to 70 years of
age and not much change after that.

Body size
Of the fourteen studies that looked for associations between the
factor ‘body size’ and n-3 LCPUFA levels(10,11,47,49,52,58–61,63–67),
eight studies used ‘BMI’(11,47,49,52,60,63–65), three used
‘girth’(58,59,61) and three studies(10,66,67) used both to compare
the weight-based association and n-3 LCPUFA. Despite the
strong correlations, we chose to report BMI and girth in relation
to n-3 LCPUFA separately, because they provide different
information about the participants’ fat distribution and require
very different methodology for measurement.

BMI. Overall, of the eleven cross-sectional studies that investigated the association of BMI and n-3 LCPUFA levels, ﬁve
identiﬁed negative associations(10,49,64,66,67), whereas six found
no association(11,47,52,60,63,65).
As shown in Table 3, it appears that there is no association
when erythrocyte EPA and DHA is >7 % of total fatty acids and
that there is a negative association when it is lower than 5·6 % of
the total fatty acids (Table 3). An exception to this is the study
by Block et al.(52) in which the mean erythrocyte EPA and DHA
was 4·3 % and no association was found, wherein this
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Table 2. Comparison of major allele with minor allele (homozygous or heterozygous plus homozygous) for ELOVL2 on fatty acid levels
(Percentage increase or percentage decrease)*†
rs953413 (ELOVL2)
Fatty acid
20 : 5n-3
22 : 5n-3
22 : 6n-3

rs3734398 (ELOVL2)

rs2236212 (ELOVL2)

Gillingham(26)

Alsaleh(33)

Tanaka-InCHIANTI(31)

Tanaka-GOLDN(31)

Alsaleh(33)

Alsaleh(33)

ELOVL2 average

NS
NS
NS

NS
NS
↓7

↑ 14
NR
↓8

NS
↓ 1·1
↓7

NS
NS
↓6

NS
NS
↓6

↑2
↓1
↓6

ELOVL2, elongation of very-long-chain fatty acid 2; InCHIANTI, a study involving people in Chianti in Italy; GOLDN, Genetics of Lipid Lowering Drugs and Diet Network Study in the
USA; NR, not reported.
* NS, for the calculation of the average, NS was taken as being 0.
† The data in Table 2 are the fatty acid data taken from the publications that reported fatty acid data and then expressed as percentage increase or percentage decrease in the fatty
acid compared with the major allele (no mutation). This is a rough estimate of the magnitude of effect and therefore needs to be interpreted with caution.
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Fig. 2. Plasma EPA levels and DHA (wt% of total fatty acids) of different age groups from studies reviewed in this systematic literature review. Each line represents a
different study (population) and each symbol on a line represents an age group. Full line = significant difference between age groups measured in that study. Broken
line = no significant difference between age groups measured in that study.
, Plourde et al.(43) NS;
, Vandal et al.(42) NS;
, Sfar et al. (women)(54);
, Sfar et al. (men)(54) NS;
, Fortier et al.(40) NS;
, Dewailly et al.(58);
, Dewailly et al.(59);
, Rees et al. g1(41);
, Rees et al. g2(41);
, Rees et al. g3(41);
, Rees et al. g4(41);
, Kuriki et al.(46) NS;
, Dewailly et al.(61);
, Babin et al.(57) NS.

population group comprised mostly overweight and obese
(Table 3).

Girth. Six studies were identiﬁed dealing with girth and n-3
LCPUFA levels. Three studies(58,59,61) showed positive associations. Three studies(10,66,67) found inverse associations; one of
them(66) found this only in the obese group, another study(67)
found this only in females, whereas the third study(10) found
that 1SD increase (14·7 cm) in girth was associated with 2 %
lower n-3 LCPUFA status.
Given the small number of studies available for review and
the differing results between studies, the relationship between
girth and n-3 LCPUFA levels remains inconclusive.

Physical activity
Many studies observed associations between exercise and n-3
LCPUFA levels; however, not all studies included EPA and DHA
in their analyses(68). Therefore, only eight studies were included(11,60,63,69–73) in this review. Studies that investigated the
effect of acute exercise were excluded.
One cross-sectional study that compared muscle fatty acids in
male endurance athletes (mean training time of 74 (SD 24) min/d)
with sedentary men (no regular physical activity) showed that DHA
was approximately 30 % higher in male endurance athletes(70).
Two studies found a positive association(11,71), two studies
found a negative association(60,69), whilst four studies(63,70,72,73)
found no association between n-3 LCPUFA levels and physical
activity (Table 4).
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Erythrocyte EPA and DHA (wt % total fatty acids)
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>75

Age (years)

Fig. 3. Erythrocyte EPA levels and DHA (wt% of total fatty acids) of different
age groups from studies reviewed in this systematic literature review. Each line
represents a different study (population) and each symbol on a line represents
an age group. Full line = significant difference between age groups measured in
that study. Broken line = no significant difference between age groups
, Kawabata et al.(53) (women subjects) NS;
measured in that study.
, Kawabata et al.(53) (male subjects);
, Babin et al.(57) NS;
,
Walker et al.(39) NS.

Alcohol intake
Twelve papers were suitable for inclusion when looking at
the association between alcohol and n-3 LCPUFA
levels(11,58,59,61,63,74–80). Six papers identiﬁed positive associations(59,74–76,78,79); three found no association(11,63,77) and four
studies found negative associations(58,61,76,80). One study(76) is
mentioned twice as they found erythrocyte PL EPA to be
positively associated, whereas DHA was negatively associated.

were no studies showing negative or no associations. Three
studies had cohorts that of mostly (>88 %) wine drinkers(74,78,79),
one study separated wine from beer or spirits and found that
drinking ‘only’ wine was positively associated with n-3 LCPUFA
levels but drinking ‘only’ beer or spirits was not(75); and two
studies(59,76) did not mention the type of alcohol consumed but
consisted of participants living in locations (France and Quebec)
where wine is the most regularly consumed alcoholic beverage(74,81). Fig. 4 shows the increases in plasma EPA or DHA
associated with increasing wine intake among three studies that
had sufﬁcient data(74,75,78). The optimal amount of wine consumption seems to plateau between two to three glasses per d
(Fig. 4). In addition, it was found that erythrocyte PL EPA was
positively associated (β = 0·182, P = 0·011) with alcohol intake
in a French cohort, whereas DHA was negatively associated
(β = –0·218, P = 0·01)(76) and one study(79) found signiﬁcantly
higher DHA in phosphatidylethanolamine among wine drinkers
compared to non-drinkers (P < 0·05) but no differences in EPA.
Whilst ﬁve studies found increases in EPA with increasing alcohol
(mostly wine) intake(59,74,75,78,79), Simonetti et al.(79) and Di
Giuseppe et al.(75) were the only studies to ﬁnd a positive
association between wine intake and plasma DHA.

Alcohol type not further speciﬁed. Two studies(11,77) found
no association between alcohol and n-3 LCPUFA levels,
whereas one study(63) identiﬁed a positive association in
females only. Three studies found negative associations with
alcohol intake and EPA and/or DHA levels (Fig. 5)(58,61,80).
None of these studies reported the type of alcohol consumed by
participants, and relevant intake surveys or research to indicate
the types of drinks most commonly consumed by these populations have not been reported.

Smoking
Wine and n-3 long-chain PUFA levels. Six papers found
positive associations with wine and n-3 LCPUFA levels, and there

Twelve studies were identiﬁed(10,11,49,52,58–61,63,77,82,83) of which
eight found a negative association between smoking and n-3

Table 3. Overview of studies investigating associations between BMI and n-3 long-chain PUFA levels presented in order of decreasing erythrocyte EPA and DHA
Reference
(47)

Subjects (n) BMI range and (mean)
2

Erythrocyte EPA and DHA*: range and (mean) Association
2

Ogura
Makhoul(65)

75
330

16·5–37·8 kg/m (26·2 kg/m )
Range not given (28·1 kg/m2)
71 % overweight or obese

Itomura(60)
Sala-Vila(11)
Kuriki(63)

456
198
106

Harris(10)
Howe(67)
Sands(49)
Block(52)

3196
476
163
704

Cazzola(64)
Micallef(66)

100
124

16–38 kg/m2 (22·5 kg/m2)
21·2–38·5 kg/m2 (29·2 kg/m2)
Range not given (female mean 21·5 kg/m2) (male mean
22·3 kg/m2)
Range not given (28·4 kg/m2)
18–59 kg/m2 (female mean 34 kg/m2) (male mean 31·4 kg/m2)
18–47 kg/m2 (26·2 kg/m2)
Range not given (28 kg/m2)
Study reports most participants were overweight or obese
Range and mean not given
20–40 kg/m2 (mean not given)
Twenty-one subjects between 20 and 24·9 kg/m2
Forty subjects between 25 and 29·9 kg/m2
Sixty-three subjects between 30 and 40 kg/m2

∗

Plasma levels were converted to erythrocyte EPA + DHA using the Stark et al.(16) equation.

Range not given (9·6 %)
Erythrocyte EPA range: 0·2–9·6 %
Erythrocyte DHA range: 1·6–10·3 %
EPA + DHA range not given (9·6 %)
3·9–12·9 % (8·5 %)
Interquartile range: 6·1–8·1 % (7·1 %)
Range not given (7·1 %†)

No
No

No
No
No

Range not given (5·6 %)
Range not given (female 5·3 %) (male 5·1 %)
1·7–12·4 % (4·9 %)
Range not given (4·3 %)

Negative
Negative
Negative
No

4·2–6·3 % (3·7 %)
Range and mean not given

Negative
Negative
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Table 4. Cross-sectional studies looking at differences in n-3 long-chain PUFA levels at different physical activity levels
Reference
Sala-Vila

(11)

Kamada(71)
Itomura(60)
Sumikawa(69)

Sex

Subjects (n)

Exercise

Biomarkers reported Findings

Women and
men
Men

198

Not specified

Whole blood

6 long-distance runners
9 sprinters
10 sedentary controls
456

Athletes v. controls

Erythrocytes

Not specified

Erythrocytes

12 rowers
9 sedentary controls

Athletes v. controls

Erythrocyte PC
PS

15
16
15
19
14
84

Endurance athletes v.
untrained
Athletes v. controls

Serum

Men and
women
Sex not
specified

Andersson(70) Men
Arsic(72)

Women

Kuriki(63)

Women and
men
Men

Tepsic

(73)

endurance athletes
sedentary controls
waterpolo players
footballers
sedentary controls

23 basketballers
24 footballers
16 sedentary controls

Physical activity positively ↑ associated with
EPA and DHA
EPA higher ↑ in long-distance runners
compared with controls
No difference in DHA levels between groups
Physical activity negatively ↓ associated with
EPA and DHA
Athletes had lower ↓ DHA composition in PS
No difference in PC DHA levels
EPA not measured
No differences in EPA or DHA between
groups
No differences in EPA or DHA between
groups

Erythrocytes and
plasma

Not specified

Plasma

Athletes v. sedentary
controls

Erythrocytes and
plasma

Physical activity was not associated with
EPA and DHA
No differences in EPA or DHA between
groups

70

60

Abstainersa

30

<35g/da

0.5

35–60g/db

40

Abstainers
30 ± 3.9 ml
83 ± 4.1 ml
270 ± 4.2 ml

1.0

Abstainers
<1 drink/d
approx 2 drinks/d
>3 drinks/d

1.5

Abstainers
<1 drink/d
approx 2 drinks/d
>3 drinks/d

50

20

10

0.0

EPA and DHA concentrations in HDL phosphatidylcholines
(nmol/mg Apo Al)

35–60g/da

Abstainersa
<35g/da

2.0

Abstainers
30 ± 3.9 ml
83 ± 4.1 ml
270 ± 4.2 ml

Abstainers
<1 drink/d
approx 2 drinks/d
>3 drinks/d †

2.5

Plasma EPA and DHA (% of total fatty acids)

Abstainers
<1 drink/d
approx 2 drinks/d
>3 drinks/d

PC, phosphatidylcholine; PS, phosphatidylserine.

0
EPA*(74)
DHA(74)
(low ALA group)

EPA*(74)
DHA(74)
(high ALA group)

EPA*(75)

DHA*(75)

EPA*(78)

DHA(78)

Fig. 4. EPA and DHA levels in alcohol abstainers v. wine drinkers. Bar graph presents plasma EPA and DHA (percentage of total fatty acids) for de Lorgeril(74) and di
Giuseppe(75) studies and EPA and DHA concentration in HDL phosphatidylcholines for the Perret study(78). * P < 0·05. † DHA intake was approximately 3 × lower in
subjects who drank >3 drinks per d compared with other subjects. a,b Bars in the same study with unlike letters have significantly different fatty acid levels. ALA, αlinolenic acid.

LCPUFA levels(10,11,52,58,59,77,82,83) and four studies found no
association(49,60,61,63).
Of the twelve studies, four studies(58,59,61,83) provided
numerical data on FA levels of smokers and non-smokers.
Using the Stark et al.(16) equation or the already available
data(10,52,83), erythrocyte EPA and DHA levels in smokers and
non-smokers were determined and ranged from 6 to 17 % lower
in smokers compared with non-smokers. Three studies had no
numerical data(11,77,82), but each also reported lower n-3
LCPUFA levels among smokers compared with non-smokers.

Bioavailability factors
Chemically bound form of n-3 supplement. One study(22)
reviewed the different factors associated with the bioavailability
of n-3 LCPUFA. This review and another subsequently published study(84) showed that the chemically bound form TAG
are more bioavailable than ethyl ester (EE) forms and that there
is no enough evidence to suggest that PL (like krill oil) are more
bioavailable than the TAG form from ﬁsh oil. They also showed
that matrix effects such as sufﬁcient amounts of fat in the meal
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EPA(59)

DHA(59)

EPA(58)

DHA(58)

EPA(61)

DHA(61)

0 ml
22 ± 13.2 ml
85 ± 13.3 ml
493 ± 13.5 ml

Controlsa
EPA(75)

2.5

2.0

1.5

1.0

0.5

DHA(75)

DHA(80)

0.0

DHA in erythrocyte phosphatidylcholine (% total fatty acids)

0

0 ml
22 ± 13.2 ml
85 ± 13.3 ml
493 ± 13.5 ml

1

0 drinks/weeka
1–4 drinks/db
> 4 drinks/db

2

0 drinks/weeka
1–19 drinks/weekb
> 20 drinks/weekb

3

0 drinks/weeka
1–19 drinks/weeka
> 20 drinks/weeka

4

0 drinks/weeka
1–19 drinks/weekb
> 20 drinks/weekb

5

0 drinks/weeka
1–19 drinks/weeka
> 20 drinks/weekb

EPA and DHA in plasma (% of total fatty acids)

6

Chronic alcoholicsb

0 drinks/weeka
1–4 drinks/db
b
> 4 drinks/d

R. H. M. de Groot et al.

Fig. 5. EPA and DHA levels at different alcohol intake. di Giuseppe(75) shows EPA and DHA levels for beer and spirit drinkers. Alcohol type was not reported for the
four other studies shown in the bar graph. Bar graph presents plasma EPA and DHA (percentage of total fatty acids) for Dewailly(58,59,61) and di Giuseppe(75) studies
and DHA concentration in HDL phosphatidylcholines for the Alling study(80). a,b Bars in the same study with unlike letters are significantly different from each other.

have the greatest bioavailability effect of up to three times
higher(85). It appears that some studies from the Schuchardt
review(22) showed that the galenic form (i.e. microencapsulation, emulsiﬁcation) had an effect on increased bioavailability
(e.g. up to 4-fold(86)) of emulsiﬁcation and microencapsulation
compared with oil, whilst others showed no effect.

Krill oil v. ﬁsh oil. A review(20) identiﬁed fourteen articles

comparing krill oil and ﬁsh oil, and they found that some studies showed increased bioavailability with krill oil v. ﬁsh oil, but
other studies did not show any difference and concluded that
more studies are needed. Following the publishing of this
review, two more clinical trials have been published. One
study(87) found no difference in bioavailability of ﬁsh oil (TAGrich or EE-rich) and krill oil supplements when identical doses
were used in a 4-week intervention. Another study examined
the amount of PL in krill oil(88) and showed no difference
between krill oil with high PL content and krill oil with low PL
content in plasma n-3 LCPUFA levels. However, the high PL
supplement signiﬁcantly increased erythrocyte EPA, EPA + DHA
and n-3 PUFA concentrations compared with the low PL
supplement(88).

Conversion of plant-derived n-3, α-linolenic acid to n-3
long-chain PUFA. The International Society for the Study of
Fatty Acids and Lipids (ISSFAL) statement ﬁve (http://www.
issfal.org/statement-5) concludes that ‘With no other changes in
diet, improvement of blood DHA status can be achieved with
dietary supplements of preformed DHA, but not with supplementation of ALA, EPA, or other precursors’. Furthermore, a
comprehensive review on the metabolism of ALA and stearidonic acid (SDA, 18 : 4n-3)(21) suggests that each 1 g increase in
ALA intake results in approximately 10 % relative increase in
EPA plasma PL content, whereas no change occurs in plasma PL
DHA content. With high intake of EPA and DHA, however, the
metabolism of ALA to EPA and DHA appears to become downregulated(21). High intakes of linoleic acid (LA, 18 : 2n-6) can

also impact the metabolism of ALA to its longer chain metabolites. Furthermore, increased LA intake have been shown to
decrease the metabolism of ALA to EPA(21).
It was also demonstrated(21) that SDA intake between 0·25
and 2 g/d can increase plasma EPA anywhere from 19 to 190 %.
No superior ability was noted for SDA to increase the DHA
levels, and some studies actually noted a decrease in DHA
levels when participants consumed SDA(21).

Discussion
Besides dietary intake, many factors affect n-3 LCPUFA levels.
Generally women have higher plasma DHA compared with
men(19,23), and this appears to be independent of diet(89).
Women also have increased levels of EPA derived from ALA(90)
which is believed to be indicative of increased synthesis(91,92).
The sex differences can be explained by (1) decreased rates of
ALA β-oxidation(91,92), therefore making more ALA available for
metabolism to DHA; (2) women having more DHA in their
adipose tissue(62) and therefore can mobilise more DHA (but it
is still not known whether this occurs in non-pregnant women);
(3) the fasting state wherein NEFA are released from adipose
tissue; and women have increased NEFA compared with
men(89), and this is likely due to increased adipose tissue stores;
(4) the total fractional excursions of EPA, DPA and DHA in
plasma phosphatidylcholine were greater in younger women
(74 %) compared with men (59·6 %)(93) and (5) the inﬂuence of
different sex hormones on the n-3 pathway(94), which is likely
due to the up-regulation mechanism of oestrogen on the
desaturase–elongase n-3 pathway and a possible downregulation by testosterone(94). This may partially explain why
women >50 years of age have DHA levels that are comparable
with men. Increased requirements during pregnancy and lactation could provide a biological explanation to why higher
DHA levels have been observed in women(21). Certainly, in
very early pregnancy, the requirement to increase maternal
circulating DHA at the time of the neural tube closure is likely
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18 : 3n-3
(-Linolenic acid)

Δ-6 desaturase (FADS2)

9

18 : 4n-3
(Stearidonic acid)
Long-chain fatty acid
Elongase (ELOVL5)

20 : 4n-3
(Eicosatetraenoic acid)

Δ-5 desaturase (FADS1)

20 : 5n-3
(EPA)
Very long-chain fatty
acid elongase (ELOVL2)

22 : 5n-3
( DPAn-3)
Very long-chain fatty
acid elongase (ELOVL2)

24 : 5n-3
(Tetracosapentaenoic acid) Δ-6 desaturase (FADS2)
(TPAn-3)
18 : 2n-6
(Linoleic acid)

Δ-6 desaturase (FADS2)

22 : 6n-3
(DHA)

-Oxidation
24 : 6n-3
(Tetracosahexaenoic acid)

18 : 3n-6
(-Linolenic acid)
Long chain-fatty acid
Elongase (ELOVL5)

20 : 3n-6
(Dihomo--linolenic acid)

Δ-5 desaturase (FADS1)

20 : 4n-6
(Arachidonic acid)
Very long-chain fatty
acid elongase (ELOVL2)

22 : 4n-6
(Adrenic acid)
Very long-chain fatty
acid elongase (ELOVL2)

24 : 4n-6
(Tetracosatetraenoic acid, TPAn-6) Δ-6 desaturase (FADS2)

22 : 5n-6
(DPAn-6)

-Oxidation
24: 5n-6
(Tetracosapentaenoic acid)

Fig. 6. Mammalian PUFA synthesis pathway showing the n-3 PUFA pathway and the n-6 PUFA pathway, including the enzymes responsible for the elongation and
desaturation steps. ELOVL, elongation of very long-chain fatty acid; DPA, docosapentaenoic acid.

due to increased synthesis of DHA from ALA as well as an
increase in the mobilisation of DHA from maternal adipose and
other tissues(3). Later pregnancy shows maternal erythrocyte
DHA levels being 38 % higher in the third trimester (3·85 %)
compared with the post-partum levels (2·79 %)(95), demonstrating that the magnitude of effect of increased DHA in
pregnancy is much higher than the differences seen in nonpregnant women v. men.
In terms of genetics, when comparing the baseline crosssectional n-3 LCPUFA levels between major and minor allele
carriers for FADS1 and FADS2, we deduced that there was
decreased enzyme activity at the ﬁrst Δ-6 desaturase and Δ-5
desaturase in the minor allele carriers (Fig. 6) and therefore this
resulted in decreased levels of EPA, GLA and AA. However, as
the FADS1 and FADS2 genotypes are strongly associated,
controlling for one FADS1 or FADS2 would be sufﬁcient.
Similarly, when comparing baseline cross-sectional n-3 LCPUFA
levels between major and minor allele for ELOVL2, we deduced
that there was decreased enzyme activity between EPA and
DHA in the minor allele carriers (Fig. 6), which explains the
reduced DHA levels seen with these mutations. These ﬁndings
are supported by a meta-analysis(96). Dietary supplementation
with pre-formed EPA and DHA (1·8 g/d) may overcome these
decreased enzyme activities as EPA and DHA in minor allele
carriers were 26–30 and 8–9 % higher, respectively, than
non-carriers(33). Therefore, in supplementation trials with
pre-formed EPA and DHA, it may not be necessary to measure

the minor allele SNP. Furthermore, heritability explains 24 % of
the variance of n-3 LCPUFA levels(10), which is more relevant
than genetics alone.
It appears that higher plasma EPA and DHA levels are
associated with increased age, that is, up until 70 years of
age(10,23,39–41,44–53,55,56,58–62). Based on studies that reported no
differences in DHA levels between elderly and young
groups(42,43), those studies that included elderly participants of
over 70 years of age(42,43,57) and women aged 40–82 years
showed lower levels of plasma EPA and DHA in the 60- to 82year-olds compared with the 40- to 60-year-olds(54), which
could be explained by the 60- to 82-year-old women being
post-menopausal and therefore likely to have lower oestrogen
levels and hence lower synthesis of DHA from ALA.
Negative associations between n-3 LCPUFA levels and BMI
have been found in participants with erythrocyte EPA and DHA
of 5·6 % or lower (Table 3). No associations have been found
with higher than 7 % erythrocyte EPA and DHA and BMI. With
the contradictory evidence in terms of girth and n-3 LCPUFA
levels and taking into account that the majority of populations’
erythrocyte EPA and DHA is likely to be lower than 5·6 % of the
total fatty acids, future studies should take BMI into account in
their analyses.
The following different mechanisms have been suggested for
the negative associations occasionally observed: (1) higher
susceptibility to peroxidation in overweight and obese individuals, compared with normal-weight individuals(64,97,98),
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Table 5. Summary of factors affecting n-3 long-chain PUFA (LCPUFA) levels

Factor

Conclusion 1 and quantification

Conclusion 2 and quantification

Sex

DHA in all women is 0·12 % of total plasma
fatty acids higher than men

DHA in women aged 13–50 years is 0·16 % of total
plasma fatty acids higher than men

Genetics

BMI

Girth
Physical activity
Alcohol

Smoking

Should take factor into
account yes or no

In low fish consumers, DHA in women is Yes
0·24 % of total plasma fatty acids
higher than men
No in supplementation
Supplementation of EPA and DHA at doses of 1·8 g/d
Mutations in FADS1 and FADS2 generally
trials
seemed to overcome the genetic differences, and
result in decreased levels of EPA, GLA
therefore in supplementation trials, measuring these
and AA
mutations may not be necessary
Plasma EPA and DHA is positively associated Erythrocyte EPA and DHA tended to be positively
Yes
with age (approximately 38 % increase
associated with age (approximately 19 % increase
from age 20 to 79 years)
from age 20 to 75 years)
Yes
n-3 LCPUFA levels is negatively associated No association with erythrocyte EPA and DHA >7 %
with erythrocyte EPA and DHA of 5·6 %
or lower
Inconclusive
No
Inconclusive
No
Yes, but specified
The optimal amount of wine
No or negative association between alcohol Positive association between wine drinking and n-3
according to type and
LCPUFA levels
consumption seems to plateau
consumption and n-3 LCPUFA levels
amount of alcohol
between two and three glasses per d
(except for wine)
Smoking is negatively associated with
High intakes of n-3 LCPUFA seem to overcome this at Smoking is associated with a 6–17 %
Yes
erythrocyte EPA and DHA
least partially
lower erythrocyte EPA and DHA
TAG form is better than EE form
Yes

Bioavailability chemically-bound
form
Bioavailability krill oil v. fish oil
Inconclusive
Bioavailability ALA conversion to ALA is converted to EPA but not DHA
n-3 LCPUFA

R. H. M. de Groot et al.

Age

Conclusion 3 and quantification

No
Higher conversion of ALA to DHA in women compared
with men

FADS, fatty acid desaturase; GLA, γ-linolenic acid; AA, arachidonic acid; EE, ethyl ester; ALA, α-linolenic acid.

Downloaded from https://www.cambridge.org/core. University of Wollongong, on 14 Mar 2019 at 04:34:20, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114519000138

(2) individuals with higher BMI may be more likely to consume
lower intakes of n-3 LCPUFA(63), although the opposite was
found(49), (3) alternatively, a relationship between weight and
dose might exist for n-3 LCPUFA(99), as supported by a study
showing a three-unit rise in BMI is associated with a decrease in
the n-3 LCPUFA status by 0·3 units, independent of ﬁsh
intake(49).
There is no conclusive evidence on whether an association
exists between physical activity and n-3 LCPUFA, though several potential underlying mechanisms have been suggested(72,73,100,101), and more research is warranted. Potential
associations might depend on type, duration and intensity of
physical activity, as higher DHA in skeletal muscle was
observed in endurance athletes compared with sedentary controls(70) but not in participants who followed a low-intensity
exercise programme for 6 weeks(102). Differences in fatty acid
composition between athletes from different sports have also
been found(72,73).
The association between alcohol consumption and n-3
LCPUFA levels is either negative or neutral, except for wine
consumption where there is a positive association(59,74–76,78,79),
in particular for EPA(59,74–76,78). Studies that did not demonstrate
the type of alcohol consumed showed conﬂicting results
between papers(11,58,61,63,77,80); the majority of these showed
negative associations with alcohol intake(58,61,76,80). Mechanisms for the negative associations between alcohol intake and
n-3 LCPUFA are still not fully understood in humans; however,
animal and in vitro studies propose lipid peroxidation and
changes in desaturase activities(103–105). Different ﬁndings
observed between the studies might be due to the differences in
amounts of alcohol consumed, the regularity with which alcohol is consumed and whether participants consumed more
quantity of alcohol for prolonged periods(106).
The positive associations between wine drinking and n-3
LCPUFA seem to partly contradict the mechanisms discussed
above. This poses the question whether components in wine
other than alcohol might be responsible for the positive associations observed. This warrants further research but could
explain why one study(75) saw no association for beer or spirits
and n-3 LCPUFA but a positive association between wine and
n-3 LCPUFA. Diet is the main contributor of n-3 LCPUFA
levels(10); and therefore, differences in dietary intake between
drinkers and non-drinkers could also inﬂuence associations,
though this is not uniformly supported by the literature(11,61,63,74,107). Any research on n-3 LCPUFA levels should
capture not only alcohol consumption but also the type and
amount of alcohol.
Smoking is associated with a lower erythrocyte EPA and DHA
(from 6 to 17 % lower) and thus smoking is a factor that needs to
be controlled for in research studies. A plausible reason for
lower erythrocyte EPA and DHA in smokers compared with
non-smokers could be diet(108–110), though others suggest the
involvement of non-dietary factors, as they found this negative
association regardless of the dietary intake(10,52,77). It has been
suggested that the pro-oxidative state caused by smoking
degrades PUFA(111); n-3 LCPUFA oxidation has been shown to
be increased in smokers. Of the four studies that showed no
association between smoking and n-3 LCPUFA, three consisted
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of cohorts with high n-3 LCPUFA intakes, providing mean
annual daily intake of EPA and DHA of 1293 mg(60), 2115 mg(61)
and 885 mg/d(63), and one study had a very low number (n 13
of 163) of smokers in their cohort(49). It could be that the high
intake of n-3 LCPUFA negates the effect of smoking on erythrocyte EPA and DHA. It should be noted, however, that in the
Spanish cohort(11) the erythrocyte EPA and DHA were very
similar to the cohort of Nunavik Inuit(61), thereby showing a
negative association between smoking and erythrocyte EPA
and DHA.
The major contributor to increased bioavailability of n-3
LCPUFA appears to be fat in the meal when supplements are
being taken. The biological plausibility is that the fat in the
meal stimulates the release of pancreatic lipase necessary for
fat digestion(112). The increased bioavailability of the emulsiﬁed forms compared with the larger oil droplets supports that
these emulsiﬁed forms are more readily available for pancreatic lipase. The limited evidence suggests that the EE form
of n-3 LCPUFA is less bioavailable compared with the TAG
form. Compared to low PL krill oil, high PL krill oil resulted in
higher erythrocyte EPA and DHA(88), which has been
demonstrated in only one study. There is no deﬁnitive evidence to support that krill oil or ﬁsh oil is superior to the other
in terms of bioavailability as studies to date (1) were underpowered(22), (2) used different doses of EPA and DHA(20) and
(3) involved short duration of supplementation, that is, for
4 weeks(87), which was not enough, given the mean erythrocyte lifespan of 115 d(113). One cross-over study(22) noted
the high standard deviations, even though each person was
their own control, thereby contribute to the lack of deﬁnitive
evidence.
Supplementation with ALA increases plasma EPA but not
DHA, and high intake of LA reduces the conversion of ALA to
EPA(21). Limited evidence suggests that SDA supplementation
increases plasma EPA to a greater extent than supplementation
with ALA, but SDA supplementation does not increase plasma
DHA levels(21). More research is warranted on SDA.
Given all the non-dietary factors that are associated with n-3
LCPUFA levels as discussed above and summarised in Table 5
below (but keep in mind that ﬁsh, seafood and n-3 supplement
consumption have the biggest inﬂuence), it is difﬁcult to
stipulate how these non-dietary factors relate to each other, as
these factors are associated with n-3 LCPUFA levels and do not
show cause and effect. Furthermore, no scientiﬁc evidence is
available that shows the relationship between these factors;
however, one could speculate about these relationships. The
global data of the prevalence of smoking and drinking alcohol
are higher among males compared with females(114–116).
Therefore, future investigators should consider when studying
males, who smoke more than women do and drink more
alcohol than wine, that their n-3 LCPUFA levels would likely be
lower than that in females who smoke less and drink wine
rather than beer/spirits(114–119). Furthermore, the prevalence of
overweight and obesity is high in many western countries(120,121); and taken together with the low n-3 LCPUFA levels
globally(122), the negative association between BMI and n-3
LCPUFA is also of concern. Overall, given the potential lower
levels of n-3 LCPUFA in males, they are likely to see a beneﬁt
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through n-3 LCPUFA supplementation. Conversely, given the n3 LCPUFA levels may be higher in females compared with
males, researchers need to be careful not to reach the potential
ceiling effect. Given that n-3 LCPUFA levels are positively
associated with age, researchers need to carefully consider the
age range within studies. The best advice would be to measure
the n-3 LCPUFA levels in all types of research including at
baseline and post-supplementation in clinical trials.
Whilst the focus of this systematic review was not to assess
the effect of n-3 LCPUFA interventions, a few points regarding
the importance of measuring n-3 LCPUFA levels pre- and postsupplementation are warranted. Assessing only dietary or
supplemental intake of n-3 LCPUFA is not good enough to
really demonstrate the efﬁcacy of n-3 LCPUFA supplementation. For example, a study investigating the effect of 1·4 g/d of
n-3 LCPUFA supplementation for 6 months in young people at
ultra-high risk of psychotic disorders failed to show the efﬁcacy of n-3 LCPUFA; but this was most likely due to the lack of
compliance as more than half of the participants were noncompliant, and a limitation of this study was the lack of
measuring the blood n-3 LCPUFA levels(123). Another study
measured blood n-3 LCPUFA levels pre- and postsupplementation where the participants consumed 1 g/d of
n-3 LCPUFA through the consumption of n-3 LCPUFAenriched foods, and this resulted in an increase in n-3
LCPUFA erythrocyte levels from 4 to 7·1 % of total erythrocyte
fatty acids(124). This increase in n-3 LCPUFA was associated
with improvements in arterial compliance and chronic
inﬂammation as assessed by serum C-reactive protein(124),
demonstrating the importance of measuring n-3 LCPUFA
levels pre- and post-supplementation in terms of not only
compliance but also assessing the effect of n-3 LCPUFA in
relation to health outcomes. Furthermore, we recently
reviewed the trials investigating the effect of n-3 LCPUFA
supplementation in cardiac mortality and demonstrated that
the dose of n-3 LCPUFA is important, but also ensuring that the
study populations’ n-3 LCPUFA levels are not too high at
baseline in order to alleviate a potential ceiling effect(125).
More recently two large clinical trials have been published,
where the study using high dose (4 g/d, Reduction of Cardiovascular Events with IcosapentEthyl-Intervention Trial
(REDUCE-IT)) showed efﬁcacy in cardiovascular risk reduction(126), and another study using a lower dose (1 g/d, VITamin D
and omegA-3 triaL (VITAL)) did not show efﬁcacy in the
prevention of cardiovascular disease and cancer(127). These
trials further highlight the importance of dose of n-3 LCPUFA
in clinical trials. Moreover, blood analyses of n-3 LCPUFA preand post-supplementation will (1) ensure the baseline levels
are not too high to potentially reach a ceiling effect and (2)
after supplementation show compliance to n-3 LCPUFA as
well as being able to attribute the health outcomes to the effect
of n-3 LCPUFA supplementation. Therefore, it is recommended that research into the health beneﬁts of n-3 LCPUFA
should include blood analyses of n-3 LCPUFA pre- and postsupplementation.
In conclusion, as summarised in Table 5 those scientiﬁcally
supported factors that are associated with the n-3 LCPUFA
levels must be considered in future (design of) studies. It is

recommended that blood or tissue n-3 LCPUFA levels are measured in all types of research (including cross-sectional, cohort
and clinical research), which assesses the health beneﬁts of n-3
LCPUFA. Furthermore, in randomised controlled trials, n-3
LCPUFA levels should be measured pre- and postsupplementation. It is beyond the scope of this review to
recommend which tissue or fraction of blood to measure, but
there are a couple of good reviews available on this topic(128,129).
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